Merck
HomeWebinarsGetting it Right. A Candid Conversation about Remote Viral Clearance Studies

Getting it Right. A Candid Conversation about Remote Viral Clearance Studies



WEBINAR

Join us as our head of project management discusses preparing for a viral clearance study from the client perspective with a technical specialist. Discover how we partner with you early on to study design and discuss study preparation considerations, potential challenges, and how we deliver best-in-class Provise™ clearance services without the need to ever travel.

In this webinar, you will:

  • Learn how Provise™ Viral Clearance services eliminate the need for travel.
  • Understand considerations to prepare for a successful study in advance.
  • Hear directly from a technical specialist who understands viral clearance study challenges and a project manager who has guided hundreds of biopharma manufacturers.

Speakers

Kristen Heslin, BS, MBA, PMP<sup>®</sup>

Kristen Heslin, BS, MBA, PMP®

Merck

Head of Business Planning and Implementation

Kristen Heslin joined Merck in 2011 and currently heads the NA and EU program management office for commercial and internal strategic projects and program management. She was previously the director of global implementation, responsible for building product characterization services. Her 20 years of experience spans toxicology services, business development, and strategic execution. Kristen holds a B.S. in biomedical sciences from Texas A&M University, an MBA from Johns Hopkins University in Maryland, and is a certified PMP (Project Management Professional) by the Project Management Institute.

Joshua Huffer

Joshua Huffer

Merck

Technical Specialist, Viral Clearance Services

Joshua Huffer is a technical specialist focused on BioReliance® biosafety testing services. Drawing on more than 19 years of experience in the biotech industry, Joshua provides biosafety scientific, technical, & regulatory consultancy in support of the pre-clinical phase through commercialization of products spanning from monoclonal antibodies (mAbs) and vaccines to cell & gene therapies. He has an MBA from Webster University in Missouri, U.S., and a B.Sc. degree in biochemistry from Virginia Tech University in Virginia, U.S.